Exome Asset Management is an innovative asset management company focusing on investing in public markets across the worldwide healthcare industry, including pharmaceuticals, biotechnology, healthcare services, and medical devices.
The firm practices two existing investment strategies: one which invests broadly across worldwide healthcare subsectors and geographies, and another that is a specialized healthcare investment fund emphasized on public company opportunities in emerging markets.
Exome Asset Management’s investment strategies are broadly diversified by geography and subsector.
Companies dedicated to the discovery, development, production and commercialization of drugs and other medications.
Companies focused on the discovery of new therapeutics, including gene and cell therapy products approaching the market.
Companies that design, manufacture and distribute instruments, consumables, reagents, and various other life science tools and services.
Companies that develop equipment used to prevent, detect, diagnose or treat an illness or disease.
Companies dedicated to facilitating treatment, including by providing care, physical facilities, or the distribution of necessary materials.
Companies involved with various other aspects of the healthcare industry.
Diversity is fundamental to worldwide investing. As such, Exome employs a staff of diverse investment professionals and support staff committed to investing for a healthier world.